Telix Pharmaceuticals Limited (TLPPF)
OTCMKTS · Delayed Price · Currency is USD
9.04
-0.18 (-1.95%)
Sep 5, 2025, 3:31 PM EDT

Telix Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
3,0395,0982,2241,5631,606818
Upgrade
Market Cap Growth
30.26%129.18%42.30%-2.70%96.45%196.48%
Upgrade
Enterprise Value
3,2485,0382,1441,4821,572801
Upgrade
Last Close Price
9.2214.976.884.725.683.00
Upgrade
PE Ratio
280.19165.02626.21---
Upgrade
PS Ratio
4.5710.526.4914.37290.85203.33
Upgrade
PB Ratio
7.2014.5021.9128.751023.7813.41
Upgrade
P/TBV Ratio
-54.1783.14109.40-53.46
Upgrade
P/FCF Ratio
315.31286.95229.72--619.12
Upgrade
P/OCF Ratio
134.29191.44136.63--540.78
Upgrade
EV/Sales Ratio
4.9310.396.2613.62284.54199.24
Upgrade
EV/EBITDA Ratio
81.5492.9555.00---
Upgrade
EV/EBIT Ratio
116.4899.4160.60---
Upgrade
EV/FCF Ratio
337.05283.58221.37--606.68
Upgrade
Debt / Equity Ratio
0.991.020.120.131.180.03
Upgrade
Debt / EBITDA Ratio
10.426.470.30---
Upgrade
Debt / FCF Ratio
43.4020.261.23--1.29
Upgrade
Asset Turnover
0.790.821.520.880.060.04
Upgrade
Inventory Turnover
10.9710.7915.3610.921.253.45
Upgrade
Quick Ratio
1.112.601.181.901.134.62
Upgrade
Current Ratio
1.332.781.412.031.254.69
Upgrade
Return on Equity (ROE)
3.14%13.92%4.55%-253.34%-198.36%-60.21%
Upgrade
Return on Assets (ROA)
2.08%5.33%9.81%-25.37%-37.95%-23.64%
Upgrade
Return on Capital (ROIC)
3.12%7.78%25.26%-97.35%-118.20%-40.13%
Upgrade
Return on Capital Employed (ROCE)
3.20%6.90%21.50%---
Upgrade
Earnings Yield
0.36%0.61%0.16%-4.53%-3.64%-4.23%
Upgrade
FCF Yield
0.32%0.35%0.43%-3.09%-2.75%0.16%
Upgrade
Buyback Yield / Dilution
37.99%-6.64%-4.21%-10.08%-9.69%-10.21%
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.